CoChat

Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis

Open access

The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.

Abstract

Osteoarthritis (OA) is a common disabling disease worldwide, with no effective and safe disease-modifying drugs (DMOAD) in the market. However, studies suggest that drugs, such as liraglutide, which possess strong potential in decreasing low-grade systemic inflammation may be effective in treating OA. Therefore, the aim of this study was to examine the anti-inflammatory, analgesic, and anti-degradative effects in OA using in vitro and in vivo experiments. The results showed that intra-articular injection of liraglutide alleviated pain-related behavior in in vivo sodium monoiodoacetate OA mouse model, which was probably driven by the GLP-1R-mediated anti-inflammatory activity of liraglutide. Moreover, liraglutide treatment significantly decreased IL-6, PGE 2 and nitric oxide secretion, and the expression of inflammatory genes in vitro in chondrocytes and macrophages in a dose-dependent manner. Additionally, liraglutide shifted polarized macrophage phenotype in vitro from the pro-inflammatory M1 phenotype to the M2 anti-inflammatory phenotype. Furthermore, liraglutide exerted anti-catabolic activity by significantly decreasing the activities of metalloproteinases and aggrecanases, a family of catabolic enzymes involved in cartilage breakdown in vitro. Overall, the findings of this study showed that liraglutide ameliorated OA-associated pain, possess anti-inflammatory and analgesic properties, and could constitute a novel therapeutic candidate for OA treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-022-05323-7

Cites

67 of 67 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Expression of GLP-1 receptor in OA human and non-OA mouse knee joint. (a) Immunohistochemical staining of human OA knee cartilage sections was performed to determine the presence of GLP-1R (Mankin score: 3/14, scale bar = 100 µm or 50 µm). (b) Immunohistochemical staining of human OA synovial membrane sections was performed to determine the presence of GLP-1R (si: subintima, i: intima, v: blood vessel, scale bar = 100 µm or 50 µm). (c) Immunohistochemical staining of non-OA mice knee joint sagittal sections to determine the presence of GLP-1R (ac: articular cartilage, m: meniscus, js: joint space, T: tibia, F: femur, bm: bone marrow, scale bar = 100 µm or 50 µm). (d) Immunohistochemical staining of non-OA mice synovial membrane sagittal sections to determine the presence of GLP-1R (sm: synovial membrane, js: joint section, m: meniscus, scale bar = 100 µm or 50 µm). Control experiment was performed without primary antibody incubation. Arrows indicate example of cells positive for GLP-1R staining.
Figure 1 Expression of GLP-1 receptor in OA human and non-OA mouse knee joint. (a) Immunohistochemical staining of human OA knee cartilage sections was performed to determine the presence of GLP-1R (Mankin score: 3/14, scale bar = 100 µm or 50 µm). (b) Immunohistochemical staining of human OA synovial membrane sections was performed to determine the presence of GLP-1R (si: subintima, i: intima, v: blood vessel, scale bar = 100 µm or 50 µm). (c) Immunohistochemical staining of non-OA mice knee joint sagittal sections to determine the presence of GLP-1R (ac: articular cartilage, m: meniscus, js: joint space, T: tibia, F: femur, bm: bone marrow, scale bar = 100 µm or 50 µm). (d) Immunohistochemical staining of non-OA mice synovial membrane sagittal sections to determine the presence of GLP-1R (sm: synovial membrane, js: joint section, m: meniscus, scale bar = 100 µm or 50 µm). Control experiment was performed without primary antibody incubation. Arrows indicate example of cells positive for GLP-1R staining.CC BY · PubMed Central
Figure 2 Liraglutide displayed analgesic effect in MIA mice models of OA. Mice knee joints were intra-articularly (IA) injected with 0.75 mg of MIA or saline on day 1. For the short-term study (a,b), treatments (liraglutide, dexamethasone, or vehicle) were injected IA on day 3 and inflammation pain sensitivity was determined by the von Frey test on day 2 (for randomization), 7, and 10 (n = 15–19 per group). For the long-term study (c), treatments were administered on days 8, 15, and 22, and von Frey tests were performed on day 7 (for randomization), 14, 21, and 28 (n = 9–10 per group). (a) Paw withdrawal threshold was assessed by von Frey filament stimulation on days 2, 7, and 10. (b) The efficacy rate of liraglutide in the MIA short-term study was analyzed using GraphPad Prism 9.0 and the EC50 value was determined at day 10 from the von Frey calculated values. (c) Paw withdrawal threshold was assessed by von Frey filament stimulation on days 0, 7, 14, 21, and 28. Arrows indicate the treatment with IA administration. Statistical analysis: Mean ± SEM. Mann–Whitney test with sequential strategy, **p < 0.01, ***p < 0.001, ****p < 0.0001 versus MIA control.
Figure 2 Liraglutide displayed analgesic effect in MIA mice models of OA. Mice knee joints were intra-articularly (IA) injected with 0.75 mg of MIA or saline on day 1. For the short-term study (a,b), treatments (liraglutide, dexamethasone, or vehicle) were injected IA on day 3 and inflammation pain sensitivity was determined by the von Frey test on day 2 (for randomization), 7, and 10 (n = 15–19 per group). For the long-term study (c), treatments were administered on days 8, 15, and 22, and von Frey tests were performed on day 7 (for randomization), 14, 21, and 28 (n = 9–10 per group). (a) Paw withdrawal threshold was assessed by von Frey filament stimulation on days 2, 7, and 10. (b) The efficacy rate of liraglutide in the MIA short-term study was analyzed using GraphPad Prism 9.0 and the EC50 value was determined at day 10 from the von Frey calculated values. (c) Paw withdrawal threshold was assessed by von Frey filament stimulation on days 0, 7, 14, 21, and 28. Arrows indicate the treatment with IA administration. Statistical analysis: Mean ± SEM. Mann–Whitney test with sequential strategy, **p < 0.01, ***p < 0.001, ****p < 0.0001 versus MIA control.CC BY · PubMed Central
Figure 3 Liraglutide displayed anti-inflammatory effect in vivo in short-term MIA mice model of OA. Mice knee joints were intra-articularly (IA) injected with 0.75 mg of MIA or saline on day 1. Treatments (liraglutide, dexamethasone, or vehicle) were IA injected on day 3 (n = 15–19 per group). At the end of the study, on day 11, the mice were euthanized, and the right knee joint was recovered for histological analyses. (a) Representative photographs of sagittal sections of the paws of mice IA injected with 0.75 mg of MIA to induce inflammation and subsequently IA treated with vehicle, liraglutide or dexamethasone (positive control). (b) Histogram representing the total synovitis score calculated from Krenn et al., synovitis score system (n = 8–9 per group). (c) Based on the results of the von Frey test on day 10 and the synovitis score obtained for each animal, a correlation curve between these two parameters was calculated using GraphPad Prism 9.0 (n = 8–9 per group). Statistical analysis: Mean ± SEM. Mann–Whitney test with sequential strategy, **p < 0.01, ****p < 0.0001 versus MIA control. Simple linear regression, ****p < 0.0001.
Figure 3 Liraglutide displayed anti-inflammatory effect in vivo in short-term MIA mice model of OA. Mice knee joints were intra-articularly (IA) injected with 0.75 mg of MIA or saline on day 1. Treatments (liraglutide, dexamethasone, or vehicle) were IA injected on day 3 (n = 15–19 per group). At the end of the study, on day 11, the mice were euthanized, and the right knee joint was recovered for histological analyses. (a) Representative photographs of sagittal sections of the paws of mice IA injected with 0.75 mg of MIA to induce inflammation and subsequently IA treated with vehicle, liraglutide or dexamethasone (positive control). (b) Histogram representing the total synovitis score calculated from Krenn et al., synovitis score system (n = 8–9 per group). (c) Based on the results of the von Frey test on day 10 and the synovitis score obtained for each animal, a correlation curve between these two parameters was calculated using GraphPad Prism 9.0 (n = 8–9 per group). Statistical analysis: Mean ± SEM. Mann–Whitney test with sequential strategy, **p < 0.01, ****p < 0.0001 versus MIA control. Simple linear regression, ****p < 0.0001.CC BY · PubMed Central
Figure 4 Anti-inflammatory effects of liraglutide in murine primary chondrocytes. Murine primary chondrocytes were stimulated with IL-1β (2 ng/mL) and co-treated with 10 doses of liraglutide (6.6, 13.3, 26.6, 53.1, 106.3, 212.5, 425, 850 nM, 1.7 and 3.4 µM) for 24 h (n = 4). (a) The inhibition rate of liraglutide in murine primary chondrocytes was analyzed using GraphPad Prism 9.0, and the IC50 values were determined for NO, PGE2, and IL-6, which were detected in the culture supernatant. (b) Relative mRNA expression of iNos, Cox2, and Tnf-α in murine primary chondrocytes co-treated for 24 h with 2 ng/mL IL-1β and liraglutide (13.3 nM, 53.1 nM, and 1 700 nM, shown in red circles in (a)) or vehicle (n = 4). Statistical analysis: Mean ± SEM, Mann–Whitney test with sequential strategy, *p < 0.05, versus stimulated control (IL-1β alone).
Figure 4 Anti-inflammatory effects of liraglutide in murine primary chondrocytes. Murine primary chondrocytes were stimulated with IL-1β (2 ng/mL) and co-treated with 10 doses of liraglutide (6.6, 13.3, 26.6, 53.1, 106.3, 212.5, 425, 850 nM, 1.7 and 3.4 µM) for 24 h (n = 4). (a) The inhibition rate of liraglutide in murine primary chondrocytes was analyzed using GraphPad Prism 9.0, and the IC50 values were determined for NO, PGE2, and IL-6, which were detected in the culture supernatant. (b) Relative mRNA expression of iNos, Cox2, and Tnf-α in murine primary chondrocytes co-treated for 24 h with 2 ng/mL IL-1β and liraglutide (13.3 nM, 53.1 nM, and 1 700 nM, shown in red circles in (a)) or vehicle (n = 4). Statistical analysis: Mean ± SEM, Mann–Whitney test with sequential strategy, *p < 0.05, versus stimulated control (IL-1β alone).CC BY · PubMed Central
Figure 5 Anti-inflammatory effects of liraglutide in murine macrophages. Murine macrophage RAW 264.7 cells were stimulated with 100 ng/mL of LPS and co-treated with 10 doses of liraglutide (6.6, 13.3, 26.6, 53.1, 106.3, 212.5, 425, 850 nM, 1.7 and 3.4 µM) for 24 h (n = 4). (a) The inhibition rate of liraglutide on RAW 264.7 cell line was analyzed by GraphPad Prism 9.0, and the IC50 values were determined for NO, PGE2, and IL-6 detected in the culture supernatant. (b) Relative mRNA expression of Il-6, Cox2, Tnf-α in RAW 264.7 cell line co-treated with LPS and liraglutide (13.3 nM, 53.1 nM, and 1 700 nM, shown in red circle in graphs (a)) or vehicle for 24 h (n = 4). (c) Relative mRNA expression of Mcp-1, Cd38, and Erg-2 in RAW 264.7 cell line treated with LPS and liraglutide (13.3 nM, 53.1 nM, and 1 700 nM, shown in red circle in (a)) or vehicle for 24 h (n = 4). Statistical analysis: Mean ± SEM, Mann–Whitney test with sequential strategy, *p < 0.05, versus stimulated control (LPS alone).
Figure 5 Anti-inflammatory effects of liraglutide in murine macrophages. Murine macrophage RAW 264.7 cells were stimulated with 100 ng/mL of LPS and co-treated with 10 doses of liraglutide (6.6, 13.3, 26.6, 53.1, 106.3, 212.5, 425, 850 nM, 1.7 and 3.4 µM) for 24 h (n = 4). (a) The inhibition rate of liraglutide on RAW 264.7 cell line was analyzed by GraphPad Prism 9.0, and the IC50 values were determined for NO, PGE2, and IL-6 detected in the culture supernatant. (b) Relative mRNA expression of Il-6, Cox2, Tnf-α in RAW 264.7 cell line co-treated with LPS and liraglutide (13.3 nM, 53.1 nM, and 1 700 nM, shown in red circle in graphs (a)) or vehicle for 24 h (n = 4). (c) Relative mRNA expression of Mcp-1, Cd38, and Erg-2 in RAW 264.7 cell line treated with LPS and liraglutide (13.3 nM, 53.1 nM, and 1 700 nM, shown in red circle in (a)) or vehicle for 24 h (n = 4). Statistical analysis: Mean ± SEM, Mann–Whitney test with sequential strategy, *p < 0.05, versus stimulated control (LPS alone).CC BY · PubMed Central
Figure 6 Anti-inflammatory effects of liraglutide are mediated by the GLP-1 receptor pathway. Primary cultured murine articular chondrocytes were incubated with 2 ng/mL IL-1β (a) and RAW 264.7, which were incubated with 100 ng/mL LPS (b) and co-treated with 50 nM of liraglutide or co-treated with three doses of exendin fragment 9–39 (25 nM, 50 nM, and 100 nM) for 24 h (n = 6). Nitrite, PGE2, and IL-6 concentration of the supernatant was determined. Statistical analysis: Mean ± SEM, Mann–Whitney test with sequential strategy, **p < 0.01, versus stimulated control (IL-1β or LPS) and $p < 0.05, $$p < 0.01, versus IL-1β + liraglutide or LPS + liraglutide group.
Figure 6 Anti-inflammatory effects of liraglutide are mediated by the GLP-1 receptor pathway. Primary cultured murine articular chondrocytes were incubated with 2 ng/mL IL-1β (a) and RAW 264.7, which were incubated with 100 ng/mL LPS (b) and co-treated with 50 nM of liraglutide or co-treated with three doses of exendin fragment 9–39 (25 nM, 50 nM, and 100 nM) for 24 h (n = 6). Nitrite, PGE2, and IL-6 concentration of the supernatant was determined. Statistical analysis: Mean ± SEM, Mann–Whitney test with sequential strategy, **p < 0.01, versus stimulated control (IL-1β or LPS) and $p < 0.05, $$p < 0.01, versus IL-1β + liraglutide or LPS + liraglutide group.CC BY · PubMed Central
Figure 7 Anti-catabolic effects of liraglutide on murine primary chondrocytes. Murine primary chondrocytes were co-treated with 2 ng/mL of IL-1β and 10 doses of liraglutide (6.6, 13.3, 26.6, 53.1, 106.3, 212.5, 425, 850 nM, 1.7 and 3.4 µM) for 24 h (n = 4). (a) The inhibition rate of liraglutide in murine primary chondrocytes was analyzed using GraphPad Prism 9.0 and the IC50 values were determined. The expression of MMP-3, MMP-13, and GAG (rGAG) was detected in the cell supernatant. (b) Relative mRNA expression of Adamts4, Adamts5, Mmp-3, and Mmp-13 in murine primary chondrocytes co-treated with IL-1β and liraglutide (13.3 nM, 53.1 nM, and 1 700 nM) or vehicle for 24 h (n = 4). (c) Murine primary chondrocytes were stimulated with 2 ng/mL of IL-1β and co-treated with 50 nM of liraglutide for 72 h (n = 3). The concentration of glycosaminoglycans was determined in the culture supernatant using the GAG assay. Statistical analysis: Mean ± SEM, Mann–Whitney test with sequential strategy, *p < 0.05, **p < 0.01, versus stimulated control (IL-1β alone). ns non-statistical.
Figure 7 Anti-catabolic effects of liraglutide on murine primary chondrocytes. Murine primary chondrocytes were co-treated with 2 ng/mL of IL-1β and 10 doses of liraglutide (6.6, 13.3, 26.6, 53.1, 106.3, 212.5, 425, 850 nM, 1.7 and 3.4 µM) for 24 h (n = 4). (a) The inhibition rate of liraglutide in murine primary chondrocytes was analyzed using GraphPad Prism 9.0 and the IC50 values were determined. The expression of MMP-3, MMP-13, and GAG (rGAG) was detected in the cell supernatant. (b) Relative mRNA expression of Adamts4, Adamts5, Mmp-3, and Mmp-13 in murine primary chondrocytes co-treated with IL-1β and liraglutide (13.3 nM, 53.1 nM, and 1 700 nM) or vehicle for 24 h (n = 4). (c) Murine primary chondrocytes were stimulated with 2 ng/mL of IL-1β and co-treated with 50 nM of liraglutide for 72 h (n = 3). The concentration of glycosaminoglycans was determined in the culture supernatant using the GAG assay. Statistical analysis: Mean ± SEM, Mann–Whitney test with sequential strategy, *p < 0.05, **p < 0.01, versus stimulated control (IL-1β alone). ns non-statistical.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 67 references

Cited by

See all 172

Metadata

Authors
Meurot, C., Martin, C., Sudre, L., Breton, J., Bougault, C., Rattenbach, R., Bismuth, K., Jacques, C., & Berenbaum, F.
Affiliations
Inserm (FR)
Corresponding author
Berenbaum, F.
Venue
Scientific Reports
Published
2022-01-28
Volume
12
Issue
1
Pages
1567-1567
ISSN
2045-2322 (ISSN-L)
OpenAlex
W4210711301
Cited by
160
References
67
Citations by year
2026: 50 · 2025: 70 · 2024: 25 · 2023: 9 · 2022: 6
FWCI
20.02
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Rheumatology › Osteoarthritis Treatment and Mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Proteoglycans and glycosaminoglycans research
  • Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
Keywords
liraglutide, osteoarthritis, GLP-1 receptor agonists, analgesia, anti-inflammatory activity, cartilage degeneration, chondrocytes, macrophage polarization, M1/M2 macrophages, interleukin-6, prostaglandin E2, nitric oxide, metalloproteinases, aggrecanase, intra-articular injection, disease-modifying osteoarthritis drugs
MeSH terms
Glucagon-Like Peptide-1 Receptor, RAW 264.7 Cells, Liraglutide, Glucagon-Like Peptide-1 Receptor Agonists, Analgesics, Animals, Anti-Inflammatory Agents, Disease Models, Animal, Macrophages, Male, Mice, Inbred C57BL, Nitric Oxide, Osteoarthritis, Chondrocytes, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis. https://app.cochat.ai/papers/10.1038/s41598-022-05323-7
The paper
Meurot, C., Martin, C., Sudre, L., Breton, J., Bougault, C., Rattenbach, R., Bismuth, K., Jacques, C., & Berenbaum, F. (2022). Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis. Scientific Reports. https://doi.org/10.1038/s41598-022-05323-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.